Rigor Reviewed

Rigor-Reviewed Manuscript

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.

Name: Αlpha¹ Rigor Record — Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Item: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Rating: 39
Author: Αlpha¹

Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 2 critical, 2 high issues for “Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×3−0.25★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 21 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced6 types

Numerical inconsistencies3

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Critical findings

• PERCENT: 19.1% does not match the reported count 49/264
• PERCENT: 22.8% does not match the reported count 59/266

This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of ethics, demographics, and statistical methods. The main weakness is the absence of a data availability statement, which is a notable reporting gap for a clinical trial. Minor copyedit issues and a small discrepancy in the number randomized (794 vs 796) are also present.

Both reviewers independently scored all eight dimensions and agreed on every status. The study type is interventional (phase 3 RCT). The statistics verification component recomputed a subset of tests (12 total, 7 consistent, 5 inconsistent with no decision errors), but this does not affect the pass status; the unverified tests remain unconfirmed. The integrity check flagged a minor discrepancy in the number randomized (794 vs 796) and a low-severity internal contradiction that is not a true contradiction.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT). 3 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on aldosterone dysregulation, MRAs, and the phase 2 BrigHTN and HALO trials, acknowledging both positive and negative results. The rationale for testing baxdrostat is clearly derived from the need for an alternative to MRAs and the mixed results of prior trials. The paper does not explicitly describe how limitations of prior research are addressed, but the design of a larger phase 3 trial with a broader population implicitly addresses some limitations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on aldosterone's role in hypertension and the limitations of current treatments, and it logically links this to the study's objectives.

Evidence

direct quote[Introduction, paragraph 1]

“In the 12-week phase 2 BrigHTN trial in patients with resistant hypertension, baxdrostat reduced seated office systolic blood pressure (seated-SBP) compared with placebo. However, in a phase 2 trial (HALO) in patients with uncontrolled hypertension, baxdrostat failed to show a difference in change from baseline in seated-SBP at week 8 versus placebo.”